Gefitinib, another EGFR inhibitor used to treat lung cancers 16, or cetuximab, a monoclonal antibody against EGFR, reduced the production of VEGF and CXCL8 in different cancer cells, which may explain their therapeutic efficacy 17, 18. This evidence concerns the gene EGFR and lung cancer.